CRISM THERAPEUTICS CORPORATION

(the "Company")

(*Incorporated in the British Virgin Islands with registered number 1010359*)

FORM OF PROXY

Form of Proxy for completion by holders of ordinary shares in the Company in respect of the Annual General Meeting of the Company convened for 11:00 a.m. (BST) on 26 August 2025 at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT UK.

I/We

…….....
(BLOCK LETTERS PLEASE)
of
.....
being a member of CRISM Therapeutics Corporation, hereby appoint the Chairman of the meeting, or*

.....in respect of ……..…… shares as my/our proxy to attend, speak and vote for me/us on my/our behalf at the Annual General Meeting of the Company to be held at Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT UK wherein the following resolutions, to be submitted to the meeting and at any adjournment thereof, and any other business which may properly come before the meeting and any adjournment thereof.

Please indicate with an 'X' in the appropriate space how you wish your vote to be cast. Unless otherwise instructed, the proxy will vote as thought fit or abstain.

Resolutions	***For***	***Against***	***Withheld***
1. TO receive, consider and adopt the Directors' Report, the Financial Statements and the Report of the Independent Auditors thereon for the year ended 31 December 2024.			
2. TO receive and approve the Directors' remuneration report set out in the Company's Annual Report and Accounts.			
3. TO reappoint Dr Nermeen Varawalla as a Director of the Company.			
4. TO reappoint Andrew Webb as a Director of the Company.			
5. TO reappoint Dr Chris McConville as a Director of the Company.			
6. TO reappoint Gerald Beaney as a Director of the Company.			
7. TO appoint Haysmacintyre LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorise the Directors to fix the remuneration of the auditors of the Company.			
8. TO approve the adoption of the EMI Option Plan as summarized in the circular to shareholders of the Company dated 4 August 2025.			
9. TO authorise the Directors to grant options pursuant to the EMI Option Plan.			
10. TO authorise the Directors to allot up to 3,996,182 shares in the Company pursuant to the exercise of options granted pursuant the EMI Option Plan.			
11. TO authorise the Directors to allot shares in the Company and to grant rights to subscribe for or convert any security into shares in the Company up to an amount of 19,980,911 Ordinary Shares.			
12. TO dis-apply pre-emption rights in respect of issues of up to 3,996,182 shares in the Company pursuant to the exercise of options granted pursuant the EMI Option Plan.			
13. TO dis-apply pre-emption rights in respect of issues of up to 19,980,911 Ordinary Shares for cash.			

Signature ……..... Dated.....…….day of 2025

☐ **Please tick here you are appointing more than one proxy.**

* You may, if you wish, in the space provided insert the name(s) of the person(s) of your choice to attend and vote at the meeting on your behalf.

** Please note that if the "Withheld" box is marked with an "X", the Shareholder will not be counted in the calculation of votes "For" and "Against" and the Shareholder will not be taken to have given his/her/their discretion to the Proxy, on how to vote.

Notes:

1. Every member has the right to appoint some other person(s) of their choice, who need not be a shareholder as his/her proxy to exercise all or any of his/her rights, to vote for their behalf. If you wish to appoint a person other than the Chairman, please insert the name of your chosen proxy holder in the space provided (see over). If the proxy is being appointed in relation to less than your full voting entitlement, please enter the number of shares in relation to which they are authorised to act as your proxy. If left blank your proxy will be deemed to be authorised in respect of your full voting entitlement (or if this proxy form has been issued in respect of a designated account for a shareholder, the full voting entitlement for that designated account).

2. To appoint more than one proxy you may photocopy this form. Please indicate the proxy holder's name and the number of shares in relation to which they are authorised to act as your proxy (which, in aggregate, should not exceed the number of shares held by you). Please also indicate if the proxy instruction is one of multiple instructions being given. All forms must be signed and should be returned together in the same envelope.

3. The 'Withheld Vote' option is provided to enable you to abstain on any particular resolution. However, it should be noted that a 'Vote Withheld' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.

4. Entitlement to vote and the number of votes which may be cast thereat will be determined by reference to the Register of Members of the Company at close of business (BST) on 21 August 2025. Changes to entries on the Register of Members after that time shall be disregarded in determining the rights of any person to vote.

5. The Form of Proxy must arrive at MUFG Corporate Markets, PXS, 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL during usual business hours accompanied by any Power of Attorney under which it is executed (if applicable) no later than 11.00 a.m. (BST) on 21 August 2025.